CaaMTech

CaaMTech is pioneering next-generation #psychedelic drugs for the 21st century.

[CaaMTech @CaaMTechInc]

Thank you @FastCompany for highlighting our important work in #psychedelics as a part of "15 tech startups to watch in 2022." 👨‍🔬🧪

Read @thesullivan's piece here: https://t.co/GPFA1D16nG

[CaaMTech @CaaMTechInc]

CaaMTech’s new clinical trial design solves the emergent functional unblinding problems plaguing #psychedelic medicine developers https://t.co/bdAuyIGgJI

[CaaMTech @CaaMTechInc]

Scientists at @LeibnizHKI, working in collaboration with CaaMTech, recently reported new results investigating terpene-producing enzymes in “magic” mushrooms. https://t.co/OHRCB9QfBt

[ChemBioChem @ChemBioChem]

A "Magic Mushroom" Multi-Product Sesquiterpene Synthase (Dirk Hoffmeister and co-workers) @OConnor_lab, @MPI_ICE, @UniJena, @LeibnizHKI, @microverse_exc, @CaaMTechInc #OpenAccess https://t.co/O0FQ99nkTd

[CaaMTech @CaaMTechInc]

@CaaMTechInc CEO, Dr. Andrew Chadeayne, will give two presentations at the 2023 Rocky Mountain Regional Meeting of the American Chemical Society on September 16th https://t.co/0OXJdMANQ4

[CaaMTech @CaaMTechInc]

The publication of the crystal structure of 4-AcO-EPT fumarate fumaric acid also exemplifies @CaaMTechInc's pioneering #tryptamine prodrug and SAR research https://t.co/e0tbNQgsEJ

[CaaMTech @CaaMTechInc]

Dialkyl #tryptamines have received widespread attention for their potential to treat numerous mood disorders. But secondary tryptamines, or monoalkyl tryptamines, have received almost no such attention. https://t.co/mhZ8mXKnmB

[Nick Jikomes @trikomes]

In my opinion, @CaaMTechInc is one of the most interesting startups to watch in the #psychedelics space. To learn more about what they're doing, check out my conversation with founder/CEO @AndrewChadeayne: https://t.co/fNDTFjGj4h

[CaaMTech @CaaMTechInc]

@CaaMTechInc, through its CRADA with DDRU @NIDAnews IRP (part of @NIH) and in collab with scientists from the Manke Lab at @UMassD recently published receptor binding and HTR data for the synthetic #psilocybin analog 4-PrO-DMT and related tryptamines

https://t.co/k74TAoza5P

[CaaMTech @CaaMTechInc]

CaaMTech Synthesizes and Characterizes Monoalkyl Tryptamine 4-HO-NiPT

The research lays the groundwork for the pharmacological study of monoalkyl tryptamine analogues of relatively well-characterized dialkyl tryptamines such as psilocybin and psilocin.
https://t.co/fkwJOZHbwo

[Cayman Chemical @Cayman_Forensic]

Structure–Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice: https://t.co/JKEXhkfnIi

[CaaMTech @CaaMTechInc]

Psilacetin is More Potent than Psilocybin:
@CaaMTechInc, @NIDAnews, @usonainstitute, @ResearchUGent, @UMassD and @UWyonews researchers directly compared #psilocybin with understudied #magicmushroom molecules, and synthetic analogs such as psilacetin
https://t.co/BeKsidlYbB

[Grant Glatfelter @gcglatfelter]

This was truly an amazing team effort by many folks from @usonainstitute, @CaaMTechInc, @christophestove, Manke lab, Hulley lab, and NIDA IRP DDRU.

Keep an eye out for many more publications from us investigating the #pharmacology of #psychedelics !

[Nick Jikomes @trikomes]

My most downloaded podcast episode on @substack this year was with organic chemist & @CaaMTechInc CEO @AndrewChadeayne.

It's basically a deep dive into topics related to chemistry & pharmacology of psychedelic tryptamines.

Listen here: https://t.co/GyLOglZTsz

[CaaMTech @CaaMTechInc]

New paper by @CaaMTechInc @marilyn_naeem @BarbBauerCT @UMassD @AndrewChadeayne! 4-HO-DiPT has been proposed as a more clinically-optimized alternative to #psilocybin

#psychedelic #science #chemistry #crystallography

https://t.co/VnSbbbM4Wb

[CaaMTech @CaaMTechInc]

“Two years ago, no one appreciated that aeruginascin was present in magic mushrooms,” explained CaaMTech CEO, Dr. Andrew Chadeayne.

https://t.co/AZb0LsjOyW

[Psychedelic Alpha @Psyched_Alpha]

DEA Abandons Proposal To Ban Two More Psychedelics After Being Challenged By Scientists

"In April, the agency published a notice of its intent to place the hallucinogens DOI and DOC in Schedule I of the Controlled Substances Act"

https://t.co/YKVxuzDLU9

[Psychedelic Alpha @Psyched_Alpha]

BREAKING: DEA Withdraws Proposal to Schedule 5 Psychedelic Tryptamines

The challenge was led by co-counsel Matt Zorn and @calyxlaw for @TactogenInc and @MindstateDesign, with many others involved.

This is a remarkable and unprecedented outcome.

[Graham Pechenik @graham_pechenik]

A DEA scheduling hearing on 5 psychedelic tryptamines?

4-HO-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, & DiPT

“all have a high potential for abuse, no currently accepted medical use in treatment in the US, & a lack of accepted safety for use”

Notice published today

1/2

[ACS_Omega @ACS_Omega]

▶️ Synthesis, Structural Characterization, and Pharmacological Activity of Novel Quaternary Salts of 4-Substituted Tryptamines

👥 Grant C. Glatfelter, David R. Manke & coworkers

https://t.co/rIoB4KNM06

@UMassD @NIDAnews @CaaMTechInc #Pharmaceuticals #SAR #CNS

[Michael Pollan @michaelpollan]

https://t.co/AAPecISFTj